Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: Implications for treatment of latent infection

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Reuse, Sophie ^a   Calao, Miriam ^a   Kabeya, Kabamba ^b   Guiguen, Allan ^a   Gatot, Jean Stéphane ^a   Quivy, Vincent ^a   Vanhulle, Caroline ^a   Lamine, Aurélia ^c   Vaira, Dolores ^d   Demonte, Dominique ^a   Martinelli, Valérie ^a   Veithen, Emmanuelle ^a   Cherrier, Thomas ^e   Avettand, Véronique ^f   Poutrel, Solène ^c   Piette, Jacques ^d   de Launoit, Yvan ^g   Moutschen, Michel ^d   Burny, Arsène ^a   Rouzioux, Christine ^f   De Wit, Stéphane ^b   Herbein, Georges ^h   Rohr, Olivier ^e   Collette, Yves ⁱ   Lambotte, Olivier ^c   Clumeck, Nathan ^b   Van Lint, Carine ^a   more..

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g INSTITUT DE BIOLOGIE DE LILLE   (France)

^h UNIVERSITÉ DE FRANCHE COMTÉ   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; CD8 ANTIGEN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HISTONE DEACETYLASE INHIBITOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROSTRATIN; PROTEIN KINASE C ACTIVATOR; RITONAVIR; RNA POLYMERASE II; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENZYME INHIBITOR; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PHORBOL ESTER;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; ENZYME ACTIVATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; PROVIRUS; TRANSCRIPTION INITIATION; VIRUS ACTIVATION; VIRUS EXPRESSION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION; CD8+ T LYMPHOCYTE; CELL NUCLEUS; CYTOPLASM; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED; MONOCYTE; NUCLEOSOME; VIROLOGY; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AGED; ANTI-HIV AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL NUCLEUS; CYTOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; I-KAPPA B PROTEINS; MIDDLE AGED; MONOCYTES; NF-KAPPA B; NUCLEOSOMES; PHORBOL ESTERS; VIRUS LATENCY;

EID: 67650550767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006093     Document Type: Article

References (93)

1. Bisgrove D, Lewinski M, Bushman F, Verdin E (2005) Molecular mechanisms of HIV-1 proviral latency. Expert Review of Anti-infective Therapy 3: 805-814.
2. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF (2007) Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 5: 95-106.
3. Quivy V, Adam E, Collette Y, Demonte D, Chariot A, et al. (2002) Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 76: 11091-11103.
4. Van Lint C, Emiliani S, Ott M, Verdin E (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. Embo J 15: 1112-1120.
5. El Kharroubi A, Piras G, Zensen R, Martin MA (1998) Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 18: 2535-2544.
6. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, et al. (1999) HIV-1 tat transcriptional activity is regulated by acetylation. Embo J 18: 6106-6118.
7. Jordan A, Defechereux P, Verdin E (2001) The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. Embo J 20: 1726-1738.
8. Sheridan PL, Mayall TP, Verdin E, Jones KA (1997) Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 11: 3327-3340.
9. Steger DJ, Eberharter A, John S, Grant PA, Workman JL (1998) Purified histone acetyltransferase complexes stimulate HIV-1 transcription from preassembled nucleosomal arrays. Proc Natl Acad Sci U S A 95: 12924-12929.
10. Demonte D, Quivy V, Colette Y, Van Lint C (2004) Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 68: 1231-1238.
11. Quivy V, De Walque S, Van Lint C (2007) Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies. Subcell Biochem 41: 371-396.
12. Margolis DM (2007) Confronting proviral HIV infection. Curr HIV/AIDS Rep 4: 60-64.
13. Marcello A (2006) Latency: the hidden HIV-1 challenge. Retrovirology 3: 7.
14. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM (2004) Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. Aids 18: 1101-1108.
15. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, et al. (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366: 549-555.
16. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, et al. (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195: 1762-1764.
17. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS (1999) Re-emergence of HIV after stopping therapy. Nature 401: 874-875.
18. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, et al. (2008) Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. Aids 22: 1131-1135.
19. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, et al. (2008) Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. Aids 22: 1125-1129.
20. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, et al. (2007) Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 195: 833-836.
21. Adam E, Quivy V, Bex F, Chariot A, Collette Y, et al. (2003) Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Mol Cell Biol 23: 6200-6209.
22. Bocklandt S, Blumberg PM, Hamer DH (2003) Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res 59: 89-98.
23. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, et al. (2004) Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78: 10507-10515.
24. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, et al. (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98: 3006-3015.
25. Kulkosky J, Sullivan J, Xu Y, Souder E, Hamer DH, et al. (2004) Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses 20: 497-505.
26. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA (2002) Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 76: 8118-8123.
27. Gulakowski RJ, McMahon JB, Buckheit RW Jr, Gustafson KR, Boyd MR (1997) Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res 33: 87-97.
28. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, et al. (2004) Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279: 42008-42017.
29. Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, et al. (2003) Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19: 413-423.
30. Hezareh M, Moukil MA, Szanto I, Pondarzewski M, Mouche S, et al. (2004) Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms. Antivir Chem Chemother 15: 207-222.
31. Witvrouw M, Pannecouque C, Fikkert V, Hantson A, Van Remoortel B, et al. (2003) Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry. Antivir Chem Chemother 14: 321-328.
32. Rullas J, Bermejo M, Garcia-Perez J, Beltan M, Gonzalez N, et al. (2004) Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther 9: 545-554.
33. Johnson HE, Banack SA, Cox PA (2008) Variability in content of the anti-AIDS drug candidate prostratin in Samoan populations of Homalanthus nutans. J Nat Prod 71: 2041-2044.
34. Wender PA, Kee JM, Warrington JM (2008) Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 320: 649-652.
35. Gustafson KR, Cardellina JH 2nd, McMahon JB, Gulakowski RJ, Ishitoya J, et al. (1992) A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem 35: 1978-1986.
36. Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483.
37. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865-2868.
38. Crazzolara R, Johrer K, Johnstone RW, Greil R, Kofler R, et al. (2002) Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br J Haematol 119: 965-969.
39. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749.
40. Dover GJ, Brusilow S, Charache S (1994) Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84: 339-343.
41. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, et al. (1995) Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85: 43-49.
42. Duvic M, Vu J (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16: 1111-1120.
43. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen. J Biol Chem 276: 36734-36741.
44. Johannessen CU (2000) Mechanisms of action of valproate: a commentatory. Neurochem Int 37: 103-110.
45. Tunnicliff G (1999) Actions of sodium valproate on the central nervous system. J Physiol Pharmacol 50: 347-365.
46. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
47. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
48. Marks PA (2007) Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356.
49. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-1252.
50. Hess-Stumpp H, Bracker TU, Henderson D, Politz O (2007) MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 39: 1388-1405.
51. Jordan A, Bisgrove D, Verdin E (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J 22: 1868-1877.
52. Emiliani S, Fischle W, Ott M, Van Lint C, Amella CA, et al. (1998) Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol 72: 1666-1670.
53. Butler IF, Pandrea I, Marx PA, Apetrei C (2007) HIV genetic diversity: biological and public health consequences. Curr HIV Res 5: 23-45.
54. Buonaguro L, Tornesello ML, Buonaguro FM (2007) Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 81: 10209-10219.
55. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C (2008) A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem Sci 33: 339-349.
56. Verdin E, Paras P Jr, Van Lint C (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. Embo J 12: 3249-3259.
57. Jiang G, Espeseth A, Hazuda DJ, Margolis DM (2007) c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 81: 10914-10923.
58. Lusic M, Marcello A, Cereseto A, Giacca M (2003) Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. Embo J 22: 6550-6561.
59. Chun TW, Justement JS, Moir S, Hallahan CW, Ehler LA, et al. (2001) Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies. Proc Natl Acad Sci U S A 98: 253-258.
60. Blankson JN, Persaud D, Siliciano RF (2002) The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53: 557-593.
61. Hezareh M (2005) Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug News Perspect 18: 496-500.
62. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, et al. (2007) Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. Embo J 26: 412-423.
63. Imai K, Okamoto T (2006) Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem 281: 12495-12505.
64. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, et al. (2006) NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Embo J 25: 139-149.
65. He G, Margolis DM (2002) Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 22: 2965-2973.
66. Coull JJ, He G, Melander C, Rucker VC, Dervan PB, et al. (2002) Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol 76: 12349-12354.
67. Steel A, Clark S, Teo I, Shaunak S, Nelson M, et al. (2006) No change to HIV-1 latency with valproate therapy. Aids 20: 1681-1682.
68. Hassan AH, Neely KE, Vignali M, Reese JC, Workman JL (2001) Promoter targeting of chromatin-modifying complexes. Front Biosci 6: D1054-1064.
69. Agalioti T, Lomvardas S, Parekh B, Yie J, Maniatis T, et al. (2000) Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter. Cell 103: 667-678.
70. Koutroubas G, Merika M, Thanos D (2008) Bypassing the requirements for epigenetic modifications in gene transcription by increasing enhancer strength. Mol Cell Biol 28: 926-938.
71. Henderson A, Holloway A, Reeves R, Tremethick DJ (2004) Recruitment of SWI/SNF to the human immunodeficiency virus type 1 promoter. Mol Cell Biol 24: 389-397.
72. Watanabe H, Mizutani T, Haraguchi T, Yamamichi N, Minoguchi S, et al. (2006) SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 25: 470-479.
73. Singh M, Popowicz GM, Krajewski M, Holak TA (2007) Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. Chembiochem 8: 1308-1316.
74. Choudhary SK, Archin NM, Margolis DM (2008) Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis 197: 1162-1170.
75. Huang B, Yang XD, Zhou MM, Ozato K, Chen LF (2009) Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol 29: 1375-1387.
76. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, et al. (2005) The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 19: 523-534.
77. Yang Z, Yik JH, Chen R, He N, Jang MK, et al. (2005) Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 19: 535-545.
78. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci U S A 100: 8758-8763.
79. Sung TL, Rice AP (2006) Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells. Retrovirology 3: 66.
80. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212.
81. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284: 6782-6789.
82. Katz RA, Jack-Scott E, Narezkina A, Palagin I, Boimel P, et al. (2007) Highfrequency epigenetic repression and silencing of retroviruses can be antagonized by histone deacetylase inhibitors and transcriptional activators, but uniform reactivation in cell clones is restricted by additional mechanisms. J Virol 81: 2592-2604.
83. Winslow BJ, Pomerantz RJ, Bagasra O, Trono D (1993) HIV-1 latency due to the site of proviral integration. Virology 196: 849-854.
84. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS (1987) Cytokine induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238: 800-802.
85. Weiss A, Wiskocil RL, Stobo JD (1984) The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol 133: 123-128.
86. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, et al. (2000) Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J Virol 74: 3740-3751.
87. Schoonbroodt S, Ferreira V, Best-Belpomme M, Boelaert JR, Legrand-Poels S, et al. (2000) Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J Immunol 164: 4292-4300.
88. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, et al. (2004) The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. Aids 18: 1147-1158.
89. Ott M, Lovett JL, Mueller L, Verdin E (1998) Superinduction of IL-8 in T Cells by HIV-1 Tat Protein Is Mediated Through NF-{kappa}B Factors. J Immunol 160: 2872-2880.
90. Costello R, Lipcey C, Algarte M, Cerdan C, Baeuerle PA, et al. (1993) Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NF-kappa B. Cell Growth Differ 4: 329-339.
91. Costello R, Cerdan C, Pavon C, Brailly H, Hurpin C, et al. (1993) The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4+ T cells. Eur J Immunol 23: 608-613.
92. Pierres A, Lopez M, Cerdan C, Nunes J, Olive D, et al. (1988) Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)-mediated T cell activation. Eur J Immunol 18: 685-690.
93. Verdin E (1991) DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol 65: 6790-6799.